Mumbai, Aug 12: Ranbaxy Laboratories has received approval from the US Food and Drug Administration (FDA) to launch a new dosage of the amoxicillin antibiotic. Ranbaxy had developed the product under its novel drug delivery system programme, where it finds different ways of delivering existing drugs to the body.

The product is a tablet for oral suspension, said the source, who declined to be identified.
Ranbaxy's new form of amoxicillin is called DisperMox, according to the FDA Web site.
Ranbaxy, India's largest drugmaker by sales, is already selling tablets of amoxicillin and clavulanate potassium -- a generic form of GlaxoSmithKline's Augmentin antibiotic -- in the United States. Bureau Report